APC/Cyanine7 anti-mouse CD3 Antibody

Catalog# / Size	100221 / 25 µg 100222 / 100 µg
Clone	17A2
Regulatory Status	RUO
Other Names	T cell antigen receptor complex, T3
Isotype	Rat IgG2b, κ
Description	CD3, also known as T3, is a member of the Ig superfamily and primarily expressed on T cells, NK-T cells, and at different levels on thymocytes during T cell differentiation. CD3 is composed of CD3ε, δ, γ and ζ chains. It forms a TCR complex by associating with TCR α/β or γ/δ chains. CD3 plays a critical role in TCR signal transduction, T cell activation, and antigen recognition by binding the peptide/MHC antigen complex

Product Details

Verified Reactivity	Mouse
Antibody Type	Monoclonal
Host Species	Rat
Immunogen	γδTCR-positive T-T hybridoma D1
Formulation	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation	The antibody was purified by affinity chromatography, and conjugated with APC/Cyanine7 under optimal conditions.
Concentration	0.2 mg/ml
Storage & Handling	The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. **Do not freeze.**
Application	FC - *Quality tested*
Recommended Usage	Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is =0.25 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.
Excitation Laser	Red Laser (633 nm)
Application Notes	Additional reported application (for relevant formats) include: spatial biology (IBEX)[1,2].
Additional Product Notes	BioLegend is in the process of converting the name APC/Cy7 to APC/Cyanine7. The dye molecule remains the same, so you should expect the same quality and performance from our APC/Cyanine7 products. Please contact Technical Service if you have any questions.

Application References

1. Radtke AJ, *et al.* 2020. *Proc Natl Acad Sci U S A.* 117:33455-65. (SB) PubMed
2. Radtke AJ, *et al.* 2022. *Nat Protoc.* 17:378-401. (SB) PubMed

Product Citations

1. Mackel JJ, *et al.* 2022. Front Cell Infect Microbiol. 12:974175. PubMed
2. Chung Y, *et al.* 2014. J Vis Exp. 89: 51660. PubMed
3. Sun L, *et al.* 2021. Cancer Cell. :. PubMed
4. Ferrere G, *et al.* 2021. JCI Insight. 6:. PubMed
5. Shimizu K, *et al.* 2020. Molecular Cell. 77(5):937-950.e6.. PubMed
6. Viny AD, *et al.* 2019. Cell Stem Cell. 25:682. PubMed
7. Alissafi T, *et al.* 2018. J Clin Invest. 128:3840. PubMed
8. Israelow B, *et al.* 2020. bioRxiv. . PubMed
9. Marco Barros R, *et al.* 2016. Cell. 167: 203-218. PubMed

10. Marques RM, *et al.* 2021. Cell Death Differ. 28:3140. PubMed
11. Turner JA, *et al.* 2020. Immunity. 53:1202. PubMed
12. Chen S, *et al.* 2022. Cancer Discov. :. PubMed
13. Coleby R, *et al.* 2021. Clin Exp Rheumatol. :39. PubMed
14. Durgeau A, *et al.* 2018. Nat Commun. 9:5097. PubMed
15. Silver AC, *et al.* 2018. Heliyon. 4:e00579. PubMed
16. Diao L, *et al.* 2022. iScience. 25:105511. PubMed
17. Tirado-Gonzalez I, *et al.* 2021. Cancer Discov. 11:2924. PubMed
18. Herman JD, *et al.* 2021. Nat Commun. 12:6853. PubMed
19. Tilstam PV, *et al.* 2021. J Clin Invest. 131:. PubMed
20. Ma C, *et al.* 2021. Signal Transduct Target Ther. 6:353. PubMed
21. Leimkühler NB, *et al.* 2020. Cell Stem Cell. 28:637. PubMed
22. Haertel E, *et al.* 2018. Eur J Immunol. 48:1001. PubMed
23. Choi H *et al.* 2019. Cell Rep. 27(3):806-819 . PubMed
24. Tordesillas L, *et al.* 2018. Nat Commun. 9:5238. PubMed
25. Zheng H, *et al.* 2021. Frontiers in Cell and Developmental Biology. 9:641527. PubMed
26. Zhou Y, *et al.* 2016. Acta Pharmacol Sin. 10.1038/aps.2016.102. PubMed
27. Inoue D, *et al.* 2021. Nat Genet. 53:707. PubMed
28. Chung H, *et al.* 2021. Immune Netw. 21:e28. PubMed
29. Rafiq S, *et al.* 2018. Nat Biotechnol. 36:847. PubMed
30. Mathews J, *et al.* 2014. PLoS One. 9:97707. PubMed
31. Shi L, *et al.* 2021. Immunity. . PubMed
32. Super M, *et al.* 2021. Nat Biomed Eng. Online ahead of print. PubMed
33. Yoshimi A, *et al.* 2019. Nature. 574:273. PubMed
34. Wang Z, *et al.* 2020. Autophagy. 1:. PubMed
35. Spees A, *et al.* 2014. Infect Immun . 82:1692. PubMed
36. Wei JL, *et al.* 2021. J Immunother Cancer. 9: . PubMed
37. Han JP, *et al.* 2022. Sci Adv. 8:eabj6901. PubMed
38. Zhao F, *et al.* 2022. Front Immunol. 13:873720. PubMed
39. Kunimoto H, *et al.* 2018. Cancer Cell. 33:44. PubMed
40. Katsinas N, *et al.* 2022. J Clin Med. 11:. PubMed
41. Xue L, *et al.* 2021. BMC Cancer. 21:1134. PubMed
42. Zhang B, *et al.* 2021. Nat Biomed Eng. 5:1288. PubMed
43. Kleppe M *et al.* 2018. Cancer cell. 33(1):29-43 . PubMed
44. Pandey V, *et al.* 2021. eLife. 0.416666666666667. PubMed
45. Socodato R, *et al.* 2020. Sci Signal. 13: . PubMed
46. Liu X, *et al.* 2022. Nat Cancer. :. PubMed
47. Grune J, *et al.* 2022. Nat Cardiovasc Res. 1:649. PubMed
48. Adane B, *et al.* 2019. Cell Rep. 27:238. PubMed
49. Rashidi M, *et al.* 2019. J Immunol. 203:736. PubMed
50. Schadt L, *et al.* 2020. Cell Reports. 29(5):1236-1248.e7.. PubMed
51. Habib S, *et al.* 2018. Infect Immun. 86:e00019. PubMed
52. Harb H, *et al.* 2021. Immunity. 54(6):1186-1199.e7. PubMed
53. Alameh MG, *et al.* 2021. Immunity. 54:2877. PubMed
54. Rohner L, *et al.* 2020. Sci Rep. 0.570833333. PubMed
55. Lang V, *et al.* 2021. Elife. 10:. PubMed
56. Li X, *et al.* 2020. Nat Commun. 4.877777778. PubMed
57. Voss M, *et al.* 2015. Am J Physiol Lung Cell Mol Physiol. 309: L188 - L195. PubMed
58. Fischer FA, *et al.* 2021. Proc Natl Acad Sci U S A. 118:. PubMed
59. Robles-Oteiza C, *et al.* 2021. Dis Model Mech. 14:. PubMed
60. Li J, *et al.* 2022. Nat Commun. 13:4032. PubMed
61. Zhu W, *et al.* 2019. FASEB J. 33:5208. PubMed
62. Jandke A, *et al.* 2020. Nat Commun. 3.075694444. PubMed
63. Zhang S, *et al.* 2022. Nat Commun. 13:4744. PubMed
64. Kwok T, *et al.* 2022. Front Aging. 3:838943. PubMed
65. Miyauchi E, *et al.* 2020. Nature. 585:102. PubMed
66. Revathikumar P, *et al.* 2018. PLoS One. 13:e0193210. PubMed
67. Dhar P, *et al.* 2021. Commun Biol. 4:905. PubMed
68. Do-Thi VA, *et al.* 2021. Cancers (Basel). 13:. PubMed
69. Teater M, *et al.* 2018. Nat Commun. 9:222. PubMed
70. Draijer C, *et al.* 2018. Sci Rep. 8:5105. PubMed
71. Yin S *et al.* 2019. Cancer cell. 35(2):283-296 . PubMed
72. Sanchez HN, *et al.* 2020. Nat Commun. 0.5. PubMed
73. Bellomo A, *et al.* 2020. Immunity. 53(1):127-142.e7. PubMed
74. Kim MY, *et al.* 2022. Nat Commun. 13:3296. PubMed
75. Clemente–Casares X, *et al.* 2017. Immunity. 47:974. PubMed
76. Chen C, *et al.* 2020. Cell Rep. 2136:30. PubMed
77. Bagati A, *et al.* 2020. Cancer Cell. 39(1):54-67.e9. PubMed
78. Israelow B, *et al.* 2020. J Exp Med. 217:00:00. PubMed
79. Chao JL, *et al.* 2021. Cell Rep Med. 2:100399. PubMed
80. Rouse MD, *et al.* 2020. Front Microbiol. 11:414. PubMed
81. Katzmarski N, *et al.* 2021. Nat Immunol. 22:1382. PubMed
82. Dokoshi T, *et al.* 2020. Cell Rep. 30:61. PubMed
83. Jie Z, *et al.* 2014. J Immunol. 192:3289. PubMed
84. Szodoray P, *et al.* 2021. Cell Reports. 36(6):109525. PubMed
85. Li C, *et al.* 2021. Chem Biol Drug Des. 97:1151. PubMed
86. Sheng D, *et al.* 2022. J Immunother Cancer. 10:. PubMed
87. Luo H, *et al.* 2019. Cell Rep. 26:945. PubMed
88. Sharma R, *et al.* 2021. J Neuroinflammation. 72:18. PubMed
89. Siolas D, *et al.* 2021. Cell Reports. 36(8):109578. PubMed

90. Hildreth AD, *et al.* 2020. STAR Protoc. 1:100113. PubMed
91. Wen J, *et al.* 2015. J Pharmacol Sci. 128: 116-124. PubMed
92. Wang K, *et al.* 2021. Nat Commun. 12:4558. PubMed
93. Rodrigues KA, *et al.* 2021. Sci Adv. 7:eabj6538. PubMed
94. Kojima T, *et al.* 2016. Sci Rep. 6:36457. PubMed
95. Nakazawa S, *et al.* 2020. Sci Rep. 10:14559. PubMed

RRID

AB_2057374 (BioLegend Cat. No. 100221)
AB_2242784 (BioLegend Cat. No. 100222)

Antigen Details

Structure

Ig superfamily, CD3/TCR, 20 kD

Distribution

Thymocytes (differentiation dependent), mature T cells, NK-T cells

Function

Antigen recognition, TCR signal transduction, T cell activation

Ligand/Receptor

Peptide antigen/MHC-complex

Antigen References

1. Barclay A, *et al.* 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Davis MM. 1990. *Annu. Rev. Biochem.* 59:475.
3. Weiss A, *et al.* 1994. *Cell* 76:263.

Gene ID

12502

Related Protocols

Cell Surface Flow Cytometry Staining Protocol

Other Formats

FITC anti-mouse CD3, PE anti-mouse CD3, Purified anti-mouse CD3, Alexa Fluor® 647 anti-mouse CD3, Alexa Fluor® 488 anti-mouse CD3, Pacific Blue™ anti-mouse CD3, Alexa Fluor® 700 anti-mouse CD3, PerCP/Cyanine5.5 anti-mouse CD3, PE/Cyanine7 anti-mouse CD3, APC/Cyanine7 anti-mouse CD3, Brilliant Violet 421™ anti-mouse CD3, Brilliant Violet 570™ anti-mouse CD3, Brilliant Violet 650™ anti-mouse CD3, Brilliant Violet 785™ anti-mouse CD3, Brilliant Violet 510™ anti-mouse CD3, APC anti-mouse CD3, Ultra-LEAF™ Purified anti-mouse CD3, Brilliant Violet 605™ anti-mouse CD3, Alexa Fluor® 594 anti-mouse CD3, Brilliant Violet 711™ anti-mouse CD3, Biotin anti-mouse CD3, PE/Dazzle™ 594 anti-mouse CD3, APC/Fire™ 750 anti-mouse CD3, Brilliant Violet 750™ anti-mouse CD3, TotalSeq™-A0182 anti-mouse CD3, TotalSeq™-B0182 anti-mouse CD3, Spark Blue™ 550 anti-mouse CD3, Spark NIR™ 685 anti-mouse CD3, TotalSeq™-C0182 anti-mouse CD3, APC/Fire™ 810 anti-mouse CD3, PE/Fire™ 640 anti-mouse CD3, Spark YG™ 570 anti-mouse CD3, PE/Fire™ 700 anti-mouse CD3, PE/Cyanine5 anti-mouse CD3, Spark Blue™ 574 anti-mouse CD3 Antibody, Spark Violet™ 423 anti-mouse CD3, PE/Fire™ 810 anti-mouse CD3, Spark Red™ 718 anti-mouse CD3

Product Data



C57BL/6 splenocytes were stained with CD45R/B220 FITC and CD3 (clone 17A2) APC/Cyanine7 (left) or Rat IgG2b, κ APC/Cyanine7 isotype control (right).

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587